The statin prescription isn’t the hard part. Most of what gets taught about cholesterol management is about that first visit anyway. Which risk calculator, which statin, what intensity. The 2026 ACC/AHA multisociety dyslipidemia guideline (Blumenthal and colleagues, Circulation 2026;153:e1154) has plenty to say about that visit. I think the second visit is where it changes practice, the one where somebody looks at a repeat lipid panel and decides whether the first plan worked.
The goals. Numeric LDL-C goals are back. For an adult at high 10-year risk, 10% or greater, primary prevention starts with a high-intensity statin and an expected LDL-C reduction of at least 50%. On top of that, it’s reasonable to treat to an LDL-C under 70 mg/dL and a non-HDL-C under 100 mg/dL. For borderline risk (3% to under 5%) and intermediate risk (5% to under 10%), the goals once a statin is started are an LDL-C under 100 mg/dL and a non-HDL-C under 130 mg/dL.
Those percentages will look low to anyone trained on the older calculator. They come from the PREVENT-ASCVD equations, which the guideline now uses to estimate 10-year risk. The 2018 guideline used the Pooled Cohort Equations and considered a statin at a risk of 5% or higher. The 2026 guideline considers one at 3% or higher, and PREVENT runs 40% to 50% lower than the old calculator for the same patient. If you learned lipids in the last decade, both the calculator and the cutoffs changed.
The repeat panel. Check a lipid profile 4 to 12 weeks after starting or adjusting therapy, then every 6 to 12 months. A nonfasting sample is fine for most patients. The exception is known hypertriglyceridemia, where the sample should be fasting. For a patient who’s stable and needs no change in therapy, once a year is enough.
Response to lipid-lowering therapy varies a lot from one patient to the next. The guideline lists pharmacogenomics, diet, the patient’s lipoprotein pattern, and interactions with other medications as reasons. Adherence stays low. Both the variation in response and the poor adherence are tied to cardiovascular outcomes. So the same high-intensity statin prescription written for two patients on the same day can produce two very different results, and the lab is the only objective way to tell them apart.
The guideline judges the response by percentage reduction from baseline and by whether the absolute LDL-C and non-HDL-C goals were reached. That makes the baseline panel matter too. You can’t calculate a 50% reduction from a number nobody recorded.
Therapeutic inertia. The guideline uses that term and defines it as failure to initiate or intensify therapy when indicated. Take over a panel of cardiology patients and you’ll find this chart. The statin was started years ago and refilled on schedule, and the last LDL-C is older than the last refill. Nobody up-titrated the dose to get the patient to the new goal.
The writing committee makes two claims about the repeat panel that I’d challenge every student with. Measuring a lipid profile is associated with better medication adherence, and it reduces therapeutic inertia. The result gives the clinician and the patient something concrete to talk about, including why the pills aren’t getting taken.
What to do with the number. For the high-risk primary prevention patient, if the LDL-C isn’t under 70 mg/dL on a maximally tolerated statin, adding ezetimibe is reasonable. If it still isn’t there, a PCSK9 monoclonal antibody or bempedoic acid may be reasonable. The strength of the recommendation drops at that second step, from 2a to 2b. It’s important that clinicians know not to treat every add-on as equally supported.
The guideline also lists when to send the patient to a lipid specialist. Three of them come up in an ordinary cardiology clinic. The patient who doesn’t reach a 50% reduction and goal on a maximally tolerated statin plus a nonstatin, the patient with side effects attributed to two or more statins, and the patient with an Lp(a) of 200 nmol/L or higher (75 mg/dL or higher).
A low baseline number matters too. In an adult whose untreated LDL-C is already under 70 mg/dL and non-HDL-C under 100 mg/dL, with no additional risk factors, the guideline says starting lipid-lowering therapy for primary prevention is unlikely to reduce risk. That one carries a “no benefit” rating. A high number matters in the other direction too. A persistently high LDL-C of 160 to 189 mg/dL is a risk enhancer, so in a borderline-risk patient it can tip the decision toward starting a statin.
The second visit. For NPs and PAs, the hard work moved. Starting the statin is the easy visit. The calculator gives a category, the category gives an intensity, and the prescription gets written. The harder visit is 4 to 12 weeks later, when the LDL-C comes back at 92 mg/dL for a patient whose goal is under 70, who says they’re taking it most days, and who doesn’t want another pill.
That visit takes more clinical reasoning than the first one. Is this a response problem or an adherence problem? Is the dose maximally tolerated, or just the dose somebody started? Does ezetimibe go on today? The guideline’s benefit-risk discussion covers expected benefit, possible harms, drug interactions, cost, and patient preference, and it applies to this conversation as much as the first one.
Order the follow-up panel in the same encounter as the prescription, and write the goal in the plan. The 2026 guideline supplies the goals. Somebody still has to order the panel and act on the result. Risk calculators, CAC scoring, and the statin decision make up one of the lessons in APP Cardiology Academy.